News - Contrave


Current filters:


Popular Filters

Orexigen to resubmit US NDA for obesity drug Contrave


Along with presenting new data for its weight loss drug candidate Contrave (naltrexone SR and bupropion…

ContraveMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalRegulationResearchTakeda Pharmaceuticals

Orexigen resubmits obesity drug application in Europe

Orexigen resubmits obesity drug application in Europe


Having experienced significant delays in gaining approval for its weight-loss drug, Orexigen Therapeutics…

ContraveEuropeMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

Resubmission expected for Orexigen's obesity drug Contrave


US biopharma company Orexigen Therapeutics (Nasdaq: OREX) has announced that the Light Study independent…

Arena PharmaceuticalsBelviqContraveGastro-intestinalsNorth AmericaOrexigen TherapeuticsPharmaceuticalQnexaRegulationVivus

Orexigen updates on obesity drug filing plans


US biopharma company Orexigen Therapeutics (Nasdaq: OREX) yesterday (August 7) announced its plan to…

BiotechnologyContraveEuropeFinancialMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

Orexigen gets FDA dispute response supportive of faster path to Contrave review


The USA's Orexigen Therapeutics (Nasdaq: OREX) saw its shares jump 9.3% in early trading yesterday, after…

ContraveMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalRegulationResearch

Another FDA hurdle for Orexigen obesity drug candidate


It might seem to some that the US Food and Drug Administration has no intentions of approving any new…

ContraveMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalRegulationResearchTakeda Pharmaceuticals

Obesity drug market set to grow to $2.6 billion by 2020, says DR report


The obesity drug market will increase more than six-fold over the next decade, increasing from $420 million…

Arena PharmaceuticalsContraveLorqessMarkets & MarketingMetabolicsNovo NordiskOrexigen TherapeuticsPharmaceuticalQnexaVictozaVivus

Orexigen and FDA find way forward for obesity drug Contrave


Shares of US drug developer Orexigen Therapeutics (Nasdaq: OREX) 86% to $2.74 in extended trading yesterday,…

ContraveMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalRegulationResearchTakeda Pharmaceuticals

Blow for Orexigen as regulatory demands see firm put obesity drug Contrave on hold


Shares of US biotech firm Orexigen Therapeutics (Nasdaq: OREX) plunged 33% to $2.13 by afternoon trading…

ContraveMetabolicsNorth AmericaOrexigen TherapeuticsPharmaceuticalRegulation

Down but not out - obesity drugs continue journey towards approval


Recent studies have shown that the chances of US Food and Drug Administration approval for early-stage…

Arena PharmaceuticalsContravelorcaserinMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

Back to top